[go: up one dir, main page]

ZA200704767B - Stabilized individually coated ramipril particles, compositions and methods - Google Patents

Stabilized individually coated ramipril particles, compositions and methods

Info

Publication number
ZA200704767B
ZA200704767B ZA200704767A ZA200704767A ZA200704767B ZA 200704767 B ZA200704767 B ZA 200704767B ZA 200704767 A ZA200704767 A ZA 200704767A ZA 200704767 A ZA200704767 A ZA 200704767A ZA 200704767 B ZA200704767 B ZA 200704767B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
individually coated
ramipril particles
coated ramipril
Prior art date
Application number
ZA200704767A
Other languages
English (en)
Inventor
Wilson Edward
Martin W Beasley
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of ZA200704767B publication Critical patent/ZA200704767B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
ZA200704767A 2004-11-05 2005-11-07 Stabilized individually coated ramipril particles, compositions and methods ZA200704767B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62527004P 2004-11-05 2004-11-05

Publications (1)

Publication Number Publication Date
ZA200704767B true ZA200704767B (en) 2008-08-27

Family

ID=36319833

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200704767A ZA200704767B (en) 2004-11-05 2005-11-07 Stabilized individually coated ramipril particles, compositions and methods
ZA200704768A ZA200704768B (en) 2004-11-05 2005-11-07 Stabilized ramipril compositions and methods of making

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200704768A ZA200704768B (en) 2004-11-05 2005-11-07 Stabilized ramipril compositions and methods of making

Country Status (14)

Country Link
US (2) US20060159742A1 (fr)
EP (2) EP1824451A2 (fr)
JP (2) JP2008519063A (fr)
KR (2) KR20070085754A (fr)
CN (2) CN101098679A (fr)
AU (2) AU2005304664A1 (fr)
BR (2) BRPI0517662A (fr)
CA (2) CA2586547A1 (fr)
IL (2) IL183018A0 (fr)
MX (2) MX2007005377A (fr)
NO (2) NO20072741L (fr)
RU (2) RU2007120817A (fr)
WO (2) WO2006052968A2 (fr)
ZA (2) ZA200704767B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424192T1 (de) * 2003-06-26 2009-03-15 Teva Pharma Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
MX2007005377A (es) * 2004-11-05 2008-01-11 King Pharmaceuticals Res & Dev Particulas de ramiprilo estabilizadas, individualmente recubiertas, composiciones y metodos.
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
CA2628955A1 (fr) * 2005-11-07 2007-05-18 Edward S. Wilson Compositions de ramipril stabilise en combinaison avec un autre agent actif
MX2008013374A (es) * 2006-04-19 2008-11-12 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3.0]-octano-3-carboxilico.
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
WO2008134047A1 (fr) * 2007-04-27 2008-11-06 King Pharmaceuticals Research And Development, Inc. Procédés de traitement de l'hypertension
WO2008132756A1 (fr) * 2007-05-01 2008-11-06 Lupin Limited Compositions pharmaceutiques stables de ramipril
ITMI20072427A1 (it) * 2007-12-24 2009-06-25 I P S Internat Products & Ser Matrce polimerica polivalente a immediata disgregazione per prodotti solidi per uso orale a rilascio modificato e metodo per la sua preparazione
WO2010030735A2 (fr) * 2008-09-11 2010-03-18 Aethos Pharmaceuticals, Inc. Enrobage stabilisé destiné à des formulations pharmaceutiques
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP5719385B2 (ja) * 2010-02-24 2015-05-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ラミプリル及びベシル酸アムロジピンの固形医薬製剤及びその製造
RU2479310C2 (ru) * 2011-02-09 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения артериальной гипертензии и застойной сердечной недостаточности и способ ее получения
CN102139109A (zh) * 2011-03-30 2011-08-03 上海蓝药实业有限公司 一种质量稳定的血管紧张素转化酶抑制剂的制剂组合物
WO2013032002A1 (fr) * 2011-08-31 2013-03-07 株式会社 奈良機械製作所 Dispositif pouvant être utilisé pour la modification de la surface de particules solides et procédé de modification de la surface de particules solides
AU2012369903A1 (en) * 2012-02-17 2014-09-04 Egis Gyogyszergyar Zrt. Pharmaceutical formulation having improved stability
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
HUP1300496A2 (hu) * 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
WO2018200691A2 (fr) * 2017-04-25 2018-11-01 Proteus Digital Health, Inc. Compositions de lisinopril comportant un marqueur d'événement ingérable
ES2992213T3 (es) * 2020-02-10 2024-12-10 Adamed Pharma S A Composición que comprende ramipril e indapamida
KR20240046661A (ko) 2022-10-01 2024-04-09 김성현 높이 조절 노트북

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88621I2 (fr) * 1980-10-23 1995-09-01 Schering Corp Sandopril
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3300316A1 (de) * 1983-01-07 1984-07-12 Hoechst Ag, 6230 Frankfurt Disubstituierte prolinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE3303112A1 (de) * 1983-01-31 1984-08-09 Hoechst Ag, 6230 Frankfurt Verfahren zur racemattrennung optisch aktiver bicyclischer imino-(alpha)-carbonsaeuren
DE3315464A1 (de) * 1983-04-28 1984-10-31 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
DE3333454A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3431541A1 (de) * 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
DE3639879A1 (de) * 1986-11-21 1988-06-01 Hoechst Ag Verfahren zur herstellung von mono-, bi- und tricyclischen aminosaeuren, zwischenprodukte dieses verfahrens sowie ein verfahren zu deren herstellung
DE3722007A1 (de) * 1987-07-03 1989-01-12 Hoechst Ag Verfahren zur herstellung bicyclischer aminocarbonsaeuren, zwischenprodukte dieses verfahrens und deren verwendung
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
TW197945B (fr) * 1990-11-27 1993-01-11 Hoechst Ag
CA2128199C (fr) * 1994-07-15 1997-02-04 Bernard Charles Sherman Compositions pharmaceutiques, solides, stables, renfermant du maleate d'enalapril
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
RS50377B (sr) * 1999-08-30 2009-11-10 Sanofi-Aventis Deutschland Gmbh., Inhibitori sistema renin-angiotenzin i njihova primena
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
WO2003000235A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
US20030170309A1 (en) * 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
CA2456034A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US7022527B2 (en) * 2001-09-12 2006-04-04 National Research Council Of Canada Method for the simultaneous and direct determination of serum cholesterol in high and low density lipoproteins using infrared spectroscopy
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
US20030138486A1 (en) * 2001-10-29 2003-07-24 King Pharmaceuticals Research Methods and dosage forms for improving the bioavailability of therapeutic agents
WO2004064809A1 (fr) * 2003-01-22 2004-08-05 Sandoz Ag Composition pharmaceutique solide comprenant du ramipril
ATE424192T1 (de) * 2003-06-26 2009-03-15 Teva Pharma Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten
MX2007005377A (es) * 2004-11-05 2008-01-11 King Pharmaceuticals Res & Dev Particulas de ramiprilo estabilizadas, individualmente recubiertas, composiciones y metodos.
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation

Also Published As

Publication number Publication date
KR20070085759A (ko) 2007-08-27
MX2007005377A (es) 2008-01-11
IL183017A0 (en) 2007-09-20
AU2005301989A1 (en) 2006-05-11
EP1824451A2 (fr) 2007-08-29
KR20070085754A (ko) 2007-08-27
WO2006052968A3 (fr) 2006-10-12
US20060134213A1 (en) 2006-06-22
CA2586760A1 (fr) 2006-05-18
RU2007120817A (ru) 2008-12-10
JP2008519062A (ja) 2008-06-05
BRPI0517663A (pt) 2008-10-14
CN101098681A (zh) 2008-01-02
US20060159742A1 (en) 2006-07-20
BRPI0517662A (pt) 2008-10-14
AU2005304664A1 (en) 2006-05-18
RU2007120821A (ru) 2008-12-10
IL183018A0 (en) 2007-09-20
MX2007005373A (es) 2007-08-14
WO2006050533A2 (fr) 2006-05-11
NO20072741L (no) 2007-08-03
ZA200704768B (en) 2008-08-27
WO2006050533A3 (fr) 2006-09-14
CA2586547A1 (fr) 2006-05-11
NO20072739L (no) 2007-07-24
JP2008519063A (ja) 2008-06-05
WO2006052968A2 (fr) 2006-05-18
CN101098679A (zh) 2008-01-02
EP1817007A2 (fr) 2007-08-15

Similar Documents

Publication Publication Date Title
IL183018A0 (en) Staibilized individually coated ramipril particles, compositions and methods
ZA200700351B (en) Compounds, compositions and methods
EP1940422A4 (fr) Particules revetues d'oxyde de zinc, compositions les contenant et procedes de fabrication de celles-ci
IL229778A0 (en) Antibodies against ir-igf, their use and preparations that include them
EP1802282A4 (fr) Particules de proteines biocompatibles, dispositifs a particules et methodes associees
EP1784425A4 (fr) Anticorps anti-mcp-1, compositions, procedes et utilisations
EP1857489A4 (fr) Microparticule et composition pharmaceutique
ZA200702350B (en) Compounds for inflammation and immune-related uses
IL186127A (en) Subcutaneous preparations for the treatment of depression and methods for their preparation
IL182504A0 (en) Coating compositions, articles, and methods of coating articles
ZA200705086B (en) Catalytic materials and method for the preparation thereof
ZA200801896B (en) Slow-release composition, method for the preparation thereof, and use of the same
IL184062A0 (en) Visco-supplement composition and methods
IL179190A0 (en) Stabilizing solutions for submicronic particles, methods for making the same and methods for stabilizing submicronic particles
EP1773956A4 (fr) Composition de revetement en poudre
GB0414826D0 (en) Particulate
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
EP1910415A4 (fr) Compositions et méthodes de désagrégation des protéines
GB2413131B (en) Composite particles
GB2429705B (en) Powder particles that are uniformly coated with functional groups,method for their production and use thereof
GB0401846D0 (en) Novel particles
IL182970A0 (en) Compositions and processes for preparing 13-deoxy-anthracyclines
ZA200704988B (en) Particulate materials
ZA200707436B (en) Particle and preparation containing the particle
ZA200706038B (en) Visco-supplement composition and methods